FTI Consulting Survey Identifies Renewed Optimism as Healthcare & Life Sciences Sector Embarks on 2025

Core Insights - 79% of industry leaders express optimism about the healthcare and life sciences sector, an increase of 11% from the previous year [1] - 66% of leaders anticipate higher M&A activity in 2025, with 40% expecting improved capital-raising capabilities, reflecting renewed confidence in deal-making [2] - The industry is focusing on acquiring late-stage assets, particularly in obesity treatments, immuno-oncology, gene editing, and AI-powered drug discovery [3] Challenges and Risks - Economic uncertainty (38%) is viewed as the primary challenge, followed by cybersecurity incidents (23%) and political uncertainty (22%) [3] - Political uncertainty has gained attention due to potential implications of the U.S. presidential election [3][4] - 68% of respondents have a crisis communications plan, and 53% have engaged in crisis simulations, indicating increased preparedness for cybersecurity threats [5] Political Landscape - Nearly 60% of respondents believe a potential second Trump administration would positively impact their business [4] - Industry leaders expect a focus on reducing federal regulations and promoting market-based solutions, although significant reforms may face political hurdles [5] Survey Methodology - The survey was conducted online with 250 decision-makers in the healthcare and life sciences sector from September 24 to October 9, 2024 [7] - 43% of respondents represent large companies with over 250 employees, and approximately 35% are from publicly listed companies with an average market cap of $5 billion [7]